New brain imaging reveals how ketamine rewires the brain to lift depression

Researchers used a novel PET (positron emission tomography) tracer called [¹¹C]K-2 to visualize changes in AMPA receptors—proteins that help brain cells communicate—in the living human brain as participants received treatment. This 2026 study published in Molecular Psychiatry provides the first direct human evidence of how ketamine may repair brain connections to support relief from depression.

Led by Professor Takuya Takahashi at Yokohama City University Graduate School of Medicine in Japan, the research team combined data from three registered clinical trials. The study included 34 people diagnosed with treatment-resistant depression (TRD) alongside 49 healthy participants who served as controls. Members of the TRD group received intravenous ketamine or a placebo over a two-week period, with PET brain imaging performed before and after the treatment series. This before-and-after approach allowed the team to track how AMPA receptor density shifted across specific brain regions over time.

The results revealed that people with TRD had widespread abnormalities in AMPA receptor density compared with healthy participants. Ketamine did not produce uniform changes across the brain—instead,  improvements in depressive symptoms  were linked to dynamic, region-specific adjustments. Some cortical areas showed increased receptor density, while reductions appeared in regions associated with reward processing, especially the habenula. These region-specific shifts correlated closely with improvements in participants’ depressive symptoms, as measured by the Montgomery Åsberg Depression Rating Scale (MADRS).

Beyond explaining how ketamine works, the findings suggest that AMPA receptor PET imaging may one day serve as a biomarker—a measurable indicator that could help clinicians predict which individuals are most likely to respond to ketamine treatment. For people who have tried multiple medications without relief, this kind of personalized insight represents a meaningful step forward.

The process represents physical “rewiring”, restoring neural connections rather than simply adjusting chemical balance. This visible biological mechanism offers validation for those who have felt stuck in their treatment journey. Neuroplasticity—the brain’s ability to form new neural connections and pathways—is the foundation of ketamine’s healing potential, as explained in  the neuroscience of ketamine .

Traditional antidepressants fail many people living with depression because they target serotonin pathways when the underlying biology requires intervention in the glutamate system—an entirely different communication network in the brain. SSRIs (selective serotonin reuptake inhibitors) work for some, but approximately 30% of people  do not respond adequately to standard antidepressants, meeting the definition of treatment-resistant depression.

When medications targeting one neurotransmitter system fail to provide relief, it may indicate that the underlying biology requires a different approach. Glutamate is the brain’s primary excitatory neurotransmitter and the most abundant chemical messenger, as detailed in  the neuroscience of ketamine . While SSRIs and SNRIs focus on serotonin and norepinephrine, ketamine works through the glutamate system to repair damaged neural connections. This fundamental difference explains why some individuals who find no relief from traditional antidepressants may respond to ketamine therapy.

Side effects drive many to search for alternatives. Emotional blunting  affects 46% of people taking antidepressants, according to Goodwin et al. (2017), creating a sense of emotional distance that can feel almost as distressing as the depression itself. According to  a 2014 study by Read et al. , weight gain occurs in 65.3% of users, while sexual difficulties affect 62%, adding physical health concerns to an already challenging treatment journey. Fatigue and gastrointestinal distress round out the list of common complaints that lead people to ask whether there might be another path.

IV ketamine—delivered intravenously through a vein—acts as a catalyst for neuroplasticity rather than a daily maintenance medication. Instead of requiring ongoing daily doses to maintain therapeutic levels, ketamine therapy typically involves a series of sessions over several weeks, after which the effects may continue for months. A comparison of  ketamine vs. SSRIs  for depression highlights the distinct pathways and timelines of these approaches.

Ketamine works by temporarily blocking NMDA receptors in the brain, which triggers a surge of glutamate that activates AMPA receptors—the same receptors visualized in the 2026 imaging study. This cascade of biological activity activates pathways essential for synaptic repair and emotional regulation, creating the conditions for healing.

The treatment blocks NMDA receptors, triggering a glutamate surge that activates AMPA receptors. When NMDA receptors are temporarily inhibited, glutamate—which would normally bind to those receptors—instead binds to nearby AMPA receptors. This shift initiates a series of cellular events that strengthen existing synaptic connections and encourage the formation of new ones.

The 2026 study confirms this process activates pathways  for synaptic repair and emotional regulation. The visible changes in AMPA receptor density across brain regions demonstrate that ketamine is not merely masking symptoms but actively rebuilding the neural infrastructure that supports mood, motivation, and emotional resilience.

 Nushama  physicians administer treatments in a serene environment with ambient music, eye shades, and continuous medical monitoring. The setting matters—research shows that the experience during treatment, often described as dissociative (a sense of detachment from one’s body or environment), plays a role in the therapeutic outcome. Vitals and comfort levels are tracked throughout by physicians and nurses, ensuring both physical safety and emotional support.

IV delivery provides precise, physician-controlled dosing for safety and efficacy. Unlike oral or intranasal routes, intravenous administration allows clinicians to adjust the dose in real time based on each member’s response. This level of control reduces variability and supports consistent therapeutic outcomes.

The approach avoids the long-term side effects associated with daily oral psychiatric medications. Because ketamine sessions are time-limited and spaced over weeks rather than taken every day, members are not exposed to the cumulative effects that drive many of the complaints associated with traditional antidepressants. Members can learn more about  what to expect  during a ketamine infusion for depression and anxiety.

By repairing neural connections, ketamine may create the biological conditions that allow some members to eventually reduce their reliance on daily psychiatric medications under physician supervision. While not a simple switch, the treatment addresses the root cause—neural disconnection—rather than only managing surface symptoms.

The common question “How can I get off my psychiatry meds?” requires medical caution and individualized planning. Abrupt discontinuation of psychiatric medications can lead to withdrawal effects and symptom rebound. Any changes to medication regimens should be made gradually and under the guidance of the prescribing physician. Ketamine is  safe to use  alongside current antidepressants—no need to taper first. Members can begin ketamine therapy while continuing their existing medication regimen. This allows for a gradual, medically supervised transition if and when the time is right to adjust other treatments.

As the brain rebuilds its capacity for emotional regulation and stress response, some members may gradually reduce daily medication needs over time with their prescribing physician’s guidance. This process unfolds differently for each person and depends on factors including treatment history, symptom severity, and individual biology. According to  the 2014 study by Read et al. , withdrawal effects affect 73.5% of antidepressant users who discontinue, making medically supervised tapering essential. Symptoms can include dizziness, irritability, flu-like sensations, and mood instability. A slow, physician-guided taper minimizes these effects and supports a smoother transition. Ketamine builds nervous system flexibility and resilience, offering a potential pathway toward reduced chronic medication use for some individuals. The neuroplasticity triggered by ketamine therapy creates new neural pathways that can support improved mood and emotional regulation even after the treatment series concludes. The distinction between psychiatric vs. psychedelic medicine  helps clarify these different treatment philosophies.

Sustainable healing requires more than just a biological reset—it demands active integration to turn new neural pathways into lasting life changes. The March 2026 study shows that ketamine opens a  window of neuroplasticity  that is best utilized through therapeutic support and intentional practice.

Integration is the process of working with a coach or therapist to translate insights and experiences into daily habit changes and new patterns. The brain’s increased flexibility following ketamine treatment creates an opportunity to establish healthier thought patterns, emotional responses, and behavioral routines. Without integration support, those opportunities may not translate into durable change.

The 2025 study “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm” by Henry A MacConnel ¹, Mitch Earleywine ², and Steven Radowitz ³  followed 117 participants  with treatment-resistant PTSD. The research examined outcomes in a clinical setting that combined medical oversight with preparation and integration support. Participants experienced  symptom reduction and remission —75% and 62% respectively—nearly double national ketamine benchmarks. These results suggest that the therapeutic container surrounding the ketamine session contributes meaningfully to outcomes. Infusion-only models, where members receive ketamine without structured preparation or follow-up support, show lower rates of sustained improvement.

This comprehensive approach  combining preparation, the ketamine journey, and integration outperforms infusion-only models. Preparation helps members set intentions and understand what to expect. Integration sessions help members process their experiences and identify actionable steps to carry forward into daily life.

 Licensed therapists and integration coaches  support members in incorporating learnings into their daily lives for durable change. These practitioners help members identify patterns that emerged during treatment, address obstacles to behavior change, and build skills that support continued progress. Medicine serves as the catalyst, but the therapeutic container ensures lasting transformation through the ketamine therapy journey at Nushama.

Nushama offers medically supervised ketamine therapy with comprehensive support from consultation through integration. Our care team evaluates your full treatment history and designs a personalized protocol tailored to your specific needs.

Medical consultation evaluates full treatment history and current medications. This initial assessment ensures that ketamine therapy is appropriate and safe for you. Physicians review any contraindications, discuss your goals, and answer questions about what to expect throughout the process.

Personalized protocol designed for your specific needs and goals. Treatment plans vary based on factors including diagnosis, symptom severity, prior treatment response, and individual preferences. Some members benefit from a standard series of six infusions, while others may require adjustments to dosing or session frequency.

No requirement to discontinue existing psychiatric care before beginning. You can start ketamine therapy while continuing your current medications and therapy appointments. This continuity of care provides stability and allows for a gradual, medically informed approach to any future medication adjustments.

Scholarships and flexible payment options available. Nushama is committed to increasing access to evidence-based psychedelic therapy. Our care team can discuss financial options during your consultation.

Serene Manhattan and Rockland County locations with physician-led care. Each treatment takes place in a calm, thoughtfully designed environment that supports a safe and meaningful experience. Physicians and nurses remain present throughout every session to monitor your comfort and safety.

Visit Nushama  to learn more about how ketamine therapy may support your healing journey.

The following questions address common concerns about ketamine therapy’s safety, science, and practical considerations for those exploring this treatment option.

• Ketamine targets the glutamate system for rapid neural repair, while antidepressants modulate serotonin levels over weeks to months of daily use. Ketamine often produces noticeable effects within days. IV ketamine is delivered as a time-limited series of sessions (typically six treatments over three to six weeks) rather than as a daily pill.

• Yes, ketamine is safe to combine with most antidepressants and anxiety medications. There are no negative medication interactions at the subanesthetic doses used for depression and anxiety treatment. Medical screening during your initial consultation confirms compatibility with your specific medication regimen.

• The study provided the first direct human evidence by using PET imaging to visualize AMPA receptor changes in real time. Symptom improvements correlated with dynamic, region-specific increases in these receptors. The findings confirm that ketamine physically rewires brain communication networks rather than simply altering brain chemistry.

• IV ketamine infusions are often out-of-pocket expenses, though some reimbursement may be possible for the medical intake and psychiatric assessment portions. Nushama offers flexible payment plans and need-based scholarships to increase access. Esketamine (Spravato)—a nasal spray form of ketamine approved by the FDA—may have insurance coverage; discuss this option with the care team during your consultation.